Literature DB >> 2765444

Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach.

M P Mourits1, L Koornneef, W M Wiersinga, M F Prummel, A Berghout, R van der Gaag.   

Abstract

Patients with serious inflammatory Graves' ophthalmopathy should be treated with anti-inflammatory drugs or radiotherapy to prevent complications like fibrosis, while those with non-inflammatory ophthalmopathy may be treated by surgery immediately. It is often difficult, however, to distinguish inflammatory from non-inflammatory Graves' disease. We therefore present a simple clinical classification here to differentiate between these two conditions. This classification is based on the classical signs of inflammation--pain, redness, swelling, and impaired function. After two consecutive clinical examinations an 'activity score' can be determined, ranging from 0 to 10 points. In a retrospective study testing the efficacy of this classification we found that patients with an activity score of 3 or more at the beginning of therapy responded well to anti-inflammatory drugs, while those with a lower activity score mostly did not. Comparing the pretreatment activity score with the degree of enlargement of the extraocular muscles on the CT scan, we found a significant correlation between these two parameters: the higher the activity score, the more the enlargement of the muscles. We conclude that this classification facilitates the proper selection of patients for treatment.

Entities:  

Mesh:

Year:  1989        PMID: 2765444      PMCID: PMC1041835          DOI: 10.1136/bjo.73.8.639

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  10 in total

1.  Corticosteroids in the treatment of optic nerve involvement associated with thyroid dysfunction.

Authors:  R M Day; F D Carroll
Journal:  Trans Am Ophthalmol Soc       Date:  1967

2.  Modification of the classification of the eye changes of Graves' disease.

Authors:  S C Werner
Journal:  Am J Ophthalmol       Date:  1977-05       Impact factor: 5.258

Review 3.  Endocrine ophthalmopathy: current ideas concerning etiology, pathogenesis, and treatment.

Authors:  D H Jacobson; C A Gorman
Journal:  Endocr Rev       Date:  1984       Impact factor: 19.871

4.  Orbital Graves' disease. A modification of the "NO SPECS" classification.

Authors:  H J Van Dyk
Journal:  Ophthalmology       Date:  1981-06       Impact factor: 12.079

5.  Ocular surface drying and tear film osmolarity in thyroid eye disease.

Authors:  J P Gilbard; R L Farris
Journal:  Acta Ophthalmol (Copenh)       Date:  1983-02

6.  Ophthalmopathy of Graves' disease.

Authors:  C Gorman
Journal:  N Engl J Med       Date:  1983-02-24       Impact factor: 91.245

7.  Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study.

Authors:  G Kahaly; J Schrezenmeir; U Krause; B Schweikert; S Meuer; W Muller; R Dennebaum; J Beyer
Journal:  Eur J Clin Invest       Date:  1986-10       Impact factor: 4.686

8.  Radiation therapy for thyroid eye diseases.

Authors:  T Hurbli; D H Char; J Harris; K Weaver; F Greenspan; G Sheline
Journal:  Am J Ophthalmol       Date:  1985-06-15       Impact factor: 5.258

9.  Graves' ophthalmopathy--immunologic parameters related to corticosteroid therapy.

Authors:  R C Sergott; N T Felberg; P J Savino; J J Blizzard; N J Schatz
Journal:  Invest Ophthalmol Vis Sci       Date:  1981-02       Impact factor: 4.799

10.  Orbital compliance in Graves' eye disease.

Authors:  B R Frueh; D C Musch; R Grill; F W Garber; S Hamby
Journal:  Ophthalmology       Date:  1985-05       Impact factor: 12.079

  10 in total
  132 in total

Review 1.  Does radiotherapy have a role in the management of thyroid orbitopathy? View 1.

Authors:  Kimberley P Cockerham; John S Kennerdell
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

2.  Both Th1- and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy.

Authors:  I M Wakelkamp; M N Gerding; J W Van Der Meer; M F Prummel; W M Wiersinga
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

3.  Graves' ophthalmopathy.

Authors:  D F Dudley; J C Orcutt
Journal:  West J Med       Date:  1992-10

4.  [Diagnosis and differential diagnosis of Graves' orbitopathy in MRI].

Authors:  D Daubner; S Spieth; K Engellandt; R von Kummer
Journal:  Radiologe       Date:  2012-06       Impact factor: 0.635

5.  Lid lengthening by sclera interposition for eyelid retraction in Graves' ophthalmopathy.

Authors:  M P Mourits; L Koornneef
Journal:  Br J Ophthalmol       Date:  1991-06       Impact factor: 4.638

6.  Thyroid-associated orbitopathy.

Authors:  Adel H Alsuhaibani; Jeffrey A Nerad
Journal:  Semin Plast Surg       Date:  2007-02       Impact factor: 2.314

7.  Chemodenervation of extraocular muscles with botulinum toxin in thyroid eye disease.

Authors:  David B Granet; Nickisa Hodgson; Kyle J Godfrey; Ricardo Ventura; Don O Kikkawa; Leah Levi; Michael Kinori
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-10       Impact factor: 3.117

Review 8.  Pharmacological treatments for thyroid eye disease.

Authors:  Sara P Modjtahedi; Bobeck S Modjtahedi; Ahmad M Mansury; Dinesh Selva; Raymond S Douglas; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

9.  Regression of Ophthalmopathic Exophthalmos in Graves' Disease After Total Thyroidectomy: a Prospective Study of a Surgical Series.

Authors:  P R K Bhargav; M Sabaretnam; S Chandra Kumar; S Zwalitha; N Vimala Devi
Journal:  Indian J Surg       Date:  2016-06-22       Impact factor: 0.656

10.  Interleukin-21 is associated with disease activity in patients with Graves' disease.

Authors:  Jin Zhang; Hua Zeng; Meng Ren; Haiyan Yan; Mingtong Xu; Zhimei Feng; Weiwen Liang; Chuan Yang; Hua Cheng; Helin Ding; Li Yan
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.